Compare ALEMBIC with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs PANACEA BIOTECH - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PANACEA BIOTECH ALEMBIC/
PANACEA BIOTECH
 
P/E (TTM) x 60.8 9.0 672.0% View Chart
P/BV x 5.2 3.5 148.8% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 ALEMBIC   PANACEA BIOTECH
EQUITY SHARE DATA
    ALEMBIC
Mar-18
PANACEA BIOTECH
Mar-19
ALEMBIC/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs72354 20.4%   
Low Rs34138 24.5%   
Sales per share (Unadj.) Rs4.774.6 6.3%  
Earnings per share (Unadj.) Rs6.16.7 91.4%  
Cash flow per share (Unadj.) Rs6.215.5 40.3%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.757.2 71.1%  
Shares outstanding (eoy) m267.0361.25 436.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.33.3 341.6%   
Avg P/E ratio x8.736.8 23.6%  
P/CF ratio (eoy) x8.515.9 53.4%  
Price / Book Value ratio x1.34.3 30.3%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,13915,061 93.9%   
No. of employees `000NA2.3 0.0%   
Total wages/salary Rs m2071,471 14.1%   
Avg. sales/employee Rs ThNM1,973.6-  
Avg. wages/employee Rs ThNM635.6-  
Avg. net profit/employee Rs ThNM176.8-  
INCOME DATA
Net Sales Rs m1,2554,567 27.5%  
Other income Rs m37045 826.3%   
Total revenues Rs m1,6254,612 35.2%   
Gross profit Rs m1112,030 5.5%  
Depreciation Rs m38540 7.0%   
Interest Rs m21,048 0.2%   
Profit before tax Rs m442486 90.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2477 31.1%   
Profit after tax Rs m1,630409 398.4%  
Gross profit margin %8.944.4 19.9%  
Effective tax rate %5.415.9 34.2%   
Net profit margin %129.89.0 1,449.6%  
BALANCE SHEET DATA
Current assets Rs m1,8672,415 77.3%   
Current liabilities Rs m5919,077 6.5%   
Net working cap to sales %101.6-145.9 -69.7%  
Current ratio x3.20.3 1,187.3%  
Inventory Days Days9465 144.8%  
Debtors Days Days7471 103.7%  
Net fixed assets Rs m1,7918,333 21.5%   
Share capital Rs m53461 871.3%   
"Free" reserves Rs m10,3243,443 299.9%   
Net worth Rs m10,8583,504 309.9%   
Long term debt Rs m41461 8.9%   
Total assets Rs m11,59113,755 84.3%  
Interest coverage x260.91.5 17,822.3%   
Debt to equity ratio x00.1 2.9%  
Sales to assets ratio x0.10.3 32.6%   
Return on assets %14.110.6 132.9%  
Return on equity %15.011.7 128.6%  
Return on capital %15.238.7 39.3%  
Exports to sales %1.520.9 7.4%   
Imports to sales %21.08.1 257.6%   
Exports (fob) Rs m19954 2.0%   
Imports (cif) Rs m263372 70.8%   
Fx inflow Rs m191,203 1.6%   
Fx outflow Rs m264467 56.5%   
Net fx Rs m-244736 -33.2%   
CASH FLOW
From Operations Rs m2361,049 22.5%  
From Investments Rs m-224-54 418.7%  
From Financial Activity Rs m-27-1,011 2.6%  
Net Cashflow Rs m-15-20 75.1%  

Share Holding

Indian Promoters % 64.0 74.5 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.6 33.3%  
FIIs % 9.7 1.3 746.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 23.6 110.6%  
Shareholders   54,701 10,259 533.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  WOCKHARDT  GSK PHARMA  DR. DATSONS LABS  

Compare ALEMBIC With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Feb 25, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - ASTRAZENECA PHARMA COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS